Ultragenyx says Phase 3 Aspire missed primary, key secondary endpoints
Ultragenyx said Phase 3 Aspire of apazunersen in Angelman syndrome failed to meet its primary and key secondary endpoints.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.